TY - JOUR
T1 - One-year outcome after percutaneous coronary intervention in nonagenarians
T2 - Insights from the J-PCI OUTCOME registry
AU - Otowa, Kanichi
AU - Kohsaka, Shun
AU - Sawano, Mitsuaki
AU - Matsuura, Shintaro
AU - Chikata, Akio
AU - Maruyama, Michiro
AU - Usuda, Kazuo
AU - Watanabe, Tetsu
AU - Ishii, Hideki
AU - Amano, Tetsuya
AU - Nakamura, Masato
AU - Ikari, Yuji
N1 - Funding Information:
This work was supported by the Japanese Association of Cardiovascular Intervention and Therapeutics (CVIT; Japan), Japan Agency for Medical Research and Developments (AMED; Japan) under grant number 17ek0210097h0001, and grants from the Japan Society for the Promotion of Science Grants-in-Aid for Scientific Research (18K17332 and 21K08064). There are no relationships with industry.
Funding Information:
Mitsuaki Sawano received grants from the Japan Promotional Society for Cardiovascular Disease Sakakibara Memorial Research Grant, grants from the Japan Heart Foundation Japan Heart Foundation Research Grant, and grants from the Japan Society for the Promotion of Science Grants-in-Aid for Scientific Research (18K17332) during the conduct of the study; grants from Takeda Pharma, Takeda Japan Medical Office Funded Research Grant 2018 not relevant to the submitted study. Shun Kohsaka received investigator-initiated grant funding from Daiichi Sankyo and personal consulting fees from Bristol-Myers Squibb. Hideki Ishii received lecture fees from Astellas Pharma, AstraZeneca, Bayer, Bristol-Myers Squibb Inc., Chugai Pharma Inc., Daiichi Sankyo, Otsuka Pharma Inc., Pfizer, Mochida Pharma Inc., and MSD. Tetsuya Amano received lecture fees from Astellas Pharma, AstraZeneca, Bayer, Daiichi Sankyo, and Bristol-Myers Squibb. Taku Inohara received a research grant from Boston Scientific. Masato Nakamura received remuneration for lectures from Daiichi Sankyo, Sanofi, Bayer, Nippon Boehringer Ingelheim, Bristol-Myers Squibb, Terumo, Japan Lifeline, Abbott, Boston Scientific, Medtronic, and Nipro and an investigator-initiated grant funding from Sanofi and Daiichi Sankyo. Hideki Ishii, Tetsuya Amano, and Yuji Ikari are members of Circulation Journal's editorial team. The remaining authors have no conflicts of interest to declare.
Publisher Copyright:
© 2022 Elsevier Inc.
PY - 2022/4
Y1 - 2022/4
N2 - Background: Nonagenarian patients who undergo percutaneous coronary intervention (PCI) are increasing, and a few previous studies have reported their long-term outcomes. However, differences in their long-term outcomes between generations remain unclear. This study aimed to investigate 1-year all-cause and cardiovascular (CV) mortality, and major adverse cardiovascular events (MACE; cardiovascular death, myocardial infarction, and stroke) of nonagenarian patients who underwent PCI compared with the other elder patients, using a nationwide registration system. Methods: The patient-level data registered between January 2017 and December 2017 was extracted from the J-PCI OUTCOME Registry endorsed by the Japanese Association of Cardiovascular Intervention and Therapeutics (CVIT). The one-year all-cause and cardiovascular (CV) mortality, MACE, and major bleeding events were identified. Results: Out of 40,722 patients over 60 years of age, 880 (2.1%) were nonagenarians. For nonagenarians, the 1-year mortality rate was substantial (13.5%). The MACE and CV death rates were also high (8.1%, and 6.8%, respectively) for nonagenarians, and these event rates were approximately 1.5 times higher in nonagenarians than octogenarians. Multivariate regression analysis showed that presentation with cardiogenic shock [hazard ratio (HR) 2.32; 95 confidence intervals (CI): 1.22–4.41], or cardiac arrest (HR 2.91; 90% CI: 1.28–6.62), and use of oral anticoagulants (HR 2.10; 90% CI: 1.07–4.12) were the predictors of 1-year MACE. Conclusions: Even in the contemporary era, nonagenarians who have undergone PCI still face a considerably increased risk for adverse cardiovascular events that reduces long-term survival. In addition to having poorer lesion characteristics, adverse events, including death, MACEs, and major bleeding, occurred 1.5 times more frequently in nonagenarians than in octogenarians.
AB - Background: Nonagenarian patients who undergo percutaneous coronary intervention (PCI) are increasing, and a few previous studies have reported their long-term outcomes. However, differences in their long-term outcomes between generations remain unclear. This study aimed to investigate 1-year all-cause and cardiovascular (CV) mortality, and major adverse cardiovascular events (MACE; cardiovascular death, myocardial infarction, and stroke) of nonagenarian patients who underwent PCI compared with the other elder patients, using a nationwide registration system. Methods: The patient-level data registered between January 2017 and December 2017 was extracted from the J-PCI OUTCOME Registry endorsed by the Japanese Association of Cardiovascular Intervention and Therapeutics (CVIT). The one-year all-cause and cardiovascular (CV) mortality, MACE, and major bleeding events were identified. Results: Out of 40,722 patients over 60 years of age, 880 (2.1%) were nonagenarians. For nonagenarians, the 1-year mortality rate was substantial (13.5%). The MACE and CV death rates were also high (8.1%, and 6.8%, respectively) for nonagenarians, and these event rates were approximately 1.5 times higher in nonagenarians than octogenarians. Multivariate regression analysis showed that presentation with cardiogenic shock [hazard ratio (HR) 2.32; 95 confidence intervals (CI): 1.22–4.41], or cardiac arrest (HR 2.91; 90% CI: 1.28–6.62), and use of oral anticoagulants (HR 2.10; 90% CI: 1.07–4.12) were the predictors of 1-year MACE. Conclusions: Even in the contemporary era, nonagenarians who have undergone PCI still face a considerably increased risk for adverse cardiovascular events that reduces long-term survival. In addition to having poorer lesion characteristics, adverse events, including death, MACEs, and major bleeding, occurred 1.5 times more frequently in nonagenarians than in octogenarians.
UR - http://www.scopus.com/inward/record.url?scp=85123588550&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85123588550&partnerID=8YFLogxK
U2 - 10.1016/j.ahj.2022.01.004
DO - 10.1016/j.ahj.2022.01.004
M3 - Article
C2 - 35016854
AN - SCOPUS:85123588550
SN - 0002-8703
VL - 246
SP - 105
EP - 116
JO - American heart journal
JF - American heart journal
ER -